Molecular targeted therapy of triple-negative breast cancer
10.3760/cma.j.issn.1673-422X.2014.09.007
- VernacularTitle:三阴性乳腺癌分子靶向治疗
- Author:
Liya GONG
;
Hongfeng CHEN
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Antineoplastic agents;
Molecular targeted therapy
- From:
Journal of International Oncology
2014;(9):662-665
- CountryChina
- Language:Chinese
-
Abstract:
Treatment options are limited for triple negative breast cancer (TNBC)since endocrinother-apy and targeted therapy that aims directly at human epidermal growth factor receptor-2 (HER-2)are ineffec-tive.As such,in addition to surgical treatment,the mainstay of treatment of TNBC is systemic cytotoxic chemo-therapy.The targeted therapy of TNBC is becoming a research hotspot because of traditional chemotherapy cura-tive effect is not good enough.A large number of clinical trials have found that patients with TNBC can get ben-efits from targeted molecular strategies including poly-adenosine diphosphate glucose pyrophospheralase-ribose polymerase-1 (PARP-1 )inhibitor and epidermal growth factor receptor (EGFR)inhibitor.
